Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the tolerability and safety of three multiple
dose regimens of nebicapone (BIA 3-202 100 mg, 200 mg, and 300 mg 6 times daily) in healthy
volunteers. To characterise the steady-state pharmacokinetic and erythrocyte COMT inhibition
profiles of nebicapone in healthy volunteers.